Results 211 to 220 of about 4,582,351 (335)

Anticoagulant-related bleeding in patients receiving anticoagulant therapy over 10 years. [PDF]

Crit Care, 2023
Zhu L, Lin J.
europepmc   +1 more source

Anticoagulant therapy in children with prosthetic valves

, 1989
P. Syamasundar Rao, L. Solymár, Mohammed K. Mardini, Mohammed E. Fawzy, Gene Guinn   +4 more
openalex   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Bleeding Risk During Colorectal Endoscopic Mucosal Resection With Continued Anticoagulant Therapy: A Multicenter Study. [PDF]

Cureus
Kobayashi S, Harada K, Nawa T, Fujisawa T, Ueki T, Nasu J, Morito Y, Toyokawa T, Inaba T, Kita M, Takenaka R, Inoue M, Higashi R, Tsuduki T, Matsubara M, Yamasaki Y, Okada H, Otsuka M.   +17 more
europepmc   +1 more source

Intraocular haemorrhage associated with anticoagulant therapy [PDF]

, 2000
Clifford R. Weir, Daniel J. Nolan, D Holding, H M Hammer   +3 more
openalex   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Prognostic factors in hospitalized patients with COVID-19 pneumonia and effectiveness of prophylactic anticoagulant therapy: a single-center retrospective study. [PDF]

BMC Infect Dis
He X, Zhang C, Ji J, Liu Y, Feng W, Luo L, Fan H, Guo L.   +7 more
europepmc   +1 more source

Anticoagulant and thrombolytic therapy for cerebral embolism of cardiac origin.

, 1986
Yoshihiro Sato, Katsuhiro Mizoguchi, Yousuke Sato, Y Ohkita, Masaro Kaji   +4 more
openalex   +2 more sources

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Critical appraisal of the inclusion criteria in: "Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial" for non-severe patients. [PDF]

J Thorac Dis
de Mello Gonzaga YB, Mauad VAQ.
europepmc   +1 more source